

Arthur I Sagalowsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875941/publications.pdf>

Version: 2024-02-01

71
papers

1,755
citations

279798

23
h-index

289244

40
g-index

84
all docs

84
docs citations

84
times ranked

2546
citing authors

#	ARTICLE	IF	CITATIONS
1	Spectrum of diverse genomic alterations define non-“clear cell renal carcinoma subtypes. <i>Nature Genetics</i> , 2015, 47, 13-21.	21.4	310
2	Factors Influencing Adrenal Metastasis in Renal Cell Carcinoma. <i>Journal of Urology</i> , 1994, 151, 1181-1184.	0.4	129
3	Long-Term Patient Survival after Cystectomy For Regional Metastatic Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 1991, 146, 36-39.	0.4	101
4	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 604.e9-604.e17.	1.6	77
5	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. <i>Journal of Urology</i> , 2014, 192, 1050-1056.	0.4	76
6	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 91-100.	0.8	67
7	Testicular Tumors in Men with Human Immunodeficiency Virus. <i>Journal of Urology</i> , 1992, 147, 1038-1040.	0.4	59
8	Urologic Complications in 505 Renal transplants with Early Catheter Removal. <i>Journal of Urology</i> , 1983, 129, 929-932.	0.4	56
9	Impact of hospital case volume on testicular cancer outcomes and practice patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e7-14.e15.	1.6	55
10	A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. <i>Journal of Urology</i> , 2017, 197, 1208-1213.	0.4	45
11	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 981-988.	1.6	39
12	THE GROWTH INHIBITORY EFFECT OF p21 ADENOVIRUS ON HUMAN BLADDER CANCER CELLS. <i>Journal of Urology</i> , 2000, 163, 1033-1038.	0.4	35
13	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	0.4	35
14	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 580-589.	0.4	35
15	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	1.6	31
16	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931.	0.4	29
17	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	1.9	27
18	Association of Distance to Treatment Facility on Quality and Survival Outcomes After Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2015, 85, 876-882.	1.0	27

#	ARTICLE	IF	CITATIONS
19	Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. <i>Urology</i> , 2015, 86, 1146-1152.	1.0	25
20	Early Results with Split-Cuff Nipple Ureteral Reimplants in Urinary Diversion. <i>Journal of Urology</i> , 1995, 154, 2028-2031.	0.4	24
21	Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e23-30.e28.	1.6	24
22	Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 268.e1-268.e7.	1.6	24
23	Targeting XBP1-mediated β -catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. <i>Oncotarget</i> , 2016, 7, 56842-56854.	1.8	24
24	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15-year experience and lessons learned. <i>BMC Urology</i> , 2016, 16, 43.	1.4	24
25	Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 1671-1677.	0.4	22
26	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	1.6	21
27	Cobalamin Profiles In Patients After Urinary Diversion. <i>Journal of Urology</i> , 2002, 167, 1696-1700.	0.4	20
28	Risk Stratification of Pubertal Children and Postpubertal Adolescents with Clinical Stage I Testicular Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2014, 191, 1485-1490.	0.4	19
29	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 485.e7-485.e14.	1.6	19
30	Uncommon sites of recurrent seminoma and implications for therapy. <i>Cancer</i> , 1986, 57, 1060-1065.	4.1	18
31	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	1.0	18
32	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	1.0	15
33	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 88.e11-88.e18.	1.6	15
34	The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. <i>Journal of Urology</i> , 2016, 196, 321-326.	0.4	14
35	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. <i>European Urology Oncology</i> , 2018, 1, 242-251.	5.4	14
36	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. <i>Cancer</i> , 2020, 126, 4362-4370.	4.1	14

#	ARTICLE	IF	CITATIONS
37	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. <i>BMC Urology</i> , 2015, 15, 24.	1.4	11
38	Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma. <i>Urology</i> , 2016, 96, 44-53.	1.0	10
39	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1965-1972.	2.2	9
40	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.2	9
41	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e21-18.e26.	1.6	8
42	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99.	0.4	8
43	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 736.e11-736.e18.	1.6	8
44	Editorial Comment on: Efficacy and Safety of TachoSil Â® as Haemostatic Treatment versus Standard Suturing in Kidney Tumour Resection: A Randomised Prospective Study. <i>European Urology</i> , 2007, 52, 1162-1163.	1.9	7
45	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. <i>World Journal of Urology</i> , 2016, 34, 105-112.	2.2	7
46	Renal Transplantation in Diabetic Patients: The End Result Does Justify the Means. <i>Journal of Urology</i> , 1983, 129, 253-255.	0.4	6
47	Expression of the RNA component of human telomerase (hTR) in ThinPrepÂ® preparations from bladder washings. <i>Cancer</i> , 2001, 93, 73-79.	4.1	6
48	Radio Frequency Ablation Induced Acute Renal Failure. <i>Journal of Urology</i> , 2002, 168, 186-186.	0.4	6
49	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1218.	2.4	5
50	Cobalamin profiles in patients after urinary diversion. <i>Journal of Urology</i> , 2002, 167, 1696-700.	0.4	5
51	Signet Ring Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 1983, 130, 368-368.	0.4	4
52	Mechanisms of posttransplant hypertension. <i>World Journal of Urology</i> , 1989, 7, 102-110.	2.2	4
53	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	1.6	4
54	Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 248-253.	1.3	3

#	ARTICLE	IF	CITATIONS
55	<p>The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States</p>. Cancer Management and Research, 2020, Volume 12, 9825-9836.	1.9	3
56	Re: A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2013, 63, 579-580.	1.9	2
57	Editorial Comment. Urology, 2015, 85, 867-868.	1.0	2
58	Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. Journal of Urology, 2017, 198, 1021-1026.	0.4	2
59	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. World Journal of Urology, 2021, 39, 491-500.	2.2	2
60	Is Extended Lymphadenectomy of Beneficial Therapeutic Value for T2 Urothelial Cancer?. Journal of Urology, 2014, 191, 1206-1208.	0.4	1
61	Editorial Comment. Urology, 2014, 83, 398-399.	1.0	1
62	Re: Primary Signet Ring Cell Adenocarcinoma of the Bladder, M. L. Blute, D. E. Engen, W. D. Travis and L. K. Kvols, J. Urol, 141: 17â€“21, 1989. Journal of Urology, 1990, 143, 135-135.	0.4	0
63	StoneA. and KrederK.J.: Urinary Diversion: Scientific Foundations and Clinical Practice. New York: Taylor & Francis2004. 400 pages.. Journal of Urology, 2006, 175, 1579-1580.	0.4	0
64	Editorial Comment. Journal of Urology, 2009, 182, 1487-1487.	0.4	0
65	Editorial Comment. Urology, 2014, 84, 1334.	1.0	0
66	Editorial Comment. Urology, 2014, 84, 363.	1.0	0
67	Editorial Comment. Journal of Urology, 2015, 194, 329-329.	0.4	0
68	Risk of adverse cardiovascular events (CVE) and incident diabetes mellitus (DM) in patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT): A meta-analysis of adjusted observational results.. Journal of Clinical Oncology, 2012, 30, e15192-e15192.	1.6	0
69	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, TPS4678-TPS4678.	1.6	0
70	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 651-651.	1.6	0
71	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. Journal of Clinical Oncology, 2019, 37, e16100-e16100.	1.6	0